Opus Genetics (IRD) Price & Analysis

Compare

1,232 Followers

IRD Stock Chart & Stats

$2.36

$0.08(5.63%)

At close: Jan 08 4:00 PM EST

$2.36

$0.08(5.63%)

Day’s Range― - ―

52-Week Range$0.65 - $2.59

Previous CloseN/A

Volume154.21K

Average Volume (3M)431.43K

Market Cap

$153.79M

Enterprise Value$28.28M

Total Cash (Recent Filing)$30.82M

Total Debt (Recent Filing)$1.07M

Price to Earnings (P/E)―

Beta0.69

Next Earnings

May 08, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.25

Shares Outstanding68,964,210

10 Day Avg. Volume559,975

30 Day Avg. Volume431,433

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)4.73

Price to Sales (P/S)2.89

P/FCF Ratio-1.24

Enterprise Value/Market Cap0.18

Enterprise Value/Revenue1.93

Enterprise Value/Gross Profit34.49

Enterprise Value/Ebitda-0.66

Forecast

1Y Price Target

$8.00

Price Target Upside238.98% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial ProgressEncouraging clinical activity and a manageable safety profile were demonstrated for OPGx-LCA5, with improvements in visual acuity reported in 5 out of 6 patients.

FDA SupportOpus Genetics plans on advancing to a pivotal study for OPGx-LCA5, having gained agreement with the FDA.

Gene Therapy AdvancementsOpus Genetics seeks to address Inherited Retinal Diseases (IRD) with gene therapy, with a focus on its lead gene therapy program, OPGx-LCA5, for which there are currently no treatment options and a high unmet need.

Bears Say

Potential RisksRisks include clinical, regulatory, commercial, financing and IP.

Opus Genetics News

Opus Genetics initiated with a Buy at B. Riley

B. Riley last night initiated coverage of Opus Genetics (IRD) with a Buy rating and $9 price target...

4d ago

IRD

Opus Genetics initiated with a Buy at B. Riley

B. Riley initiated coverage of Opus Genetics (IRD) with a Buy rating and $9 price target Published first...

4d ago

IRD

Opus announces recommendation for IDMC for Phase 1/2 trial of OPGx-BEST1

Opus Genetics (IRD) announced that the Independent Data Monitoring Committee, IDMC, issued a positive recommendation to continue as...

5d ago

IRD

Opus Genetics initiated with a Buy at Brookline

Brookline initiated coverage of Opus Genetics (IRD) with a Buy rating and $8 price target Published first on...

13d ago

IRD

Opus Genetics initiated with an Overweight at Piper Sandler

Piper Sandler initiated coverage of Opus Genetics (IRD) with an Overweight rating and $7 price target The company...

19d ago

IRD

Buy These 3 Penny Stocks Now, Say Five-Star Analysts

Searching for moonshot investment opportunities? These penny stocks have been highlighted by five-star Wall Street analysts as Buys,...

23d ago

IRD

Opus Genetics doses first participant in OPGx-BEST1 Phase 1/2 trial

Opus Genetics (IRD) announced that the first participant has been dosed in the Company’s OPGx-BEST1 Phase 1/2 clinical...

1M ago

IRD

Promising Advancements in Opus Genetics’ Retinal Disease Platform Support Buy Rating

Analyst Matthew Caufield of H.C. Wainwright reiterated a Buy rating on Opus Genetics, retaining the price target of...

1M ago

IRD

Opus Genetics: Buy Rating Backed by Strong Financials, Regulatory Support, and Promising Study Progress

Wedbush analyst Yun Zhong has reiterated their bullish stance on IRD stock, giving a Buy rating on November...

1M ago

IRD

Opus Genetics reports Q3 EPS (25c) vs (29c) last year

Reports Q3 revenue $3.079M, consensus $3.08M. “We have taken critical steps in advancing our pipeline, including the positive...

1M ago

IRD

Opus Genetics Announces $23M Direct Offering

Opus Genetics ( ($IRD) ) has issued an announcement. On November 5, 2025, Opus Genetics, Inc. entered into...

1M ago

IRD

Positive Outlook for Opus Genetics: Regulatory Support and Financial Stability Justify Buy Rating

Yun Zhong, an analyst from Wedbush, maintained the Buy rating on Opus Genetics. The associated price target remains...

1M ago

IRD

Opus Genetics Announces $23 Million Direct Offering

Opus Genetics ( ($IRD) ) just unveiled an announcement. On November 6, 2025, Opus Genetics announced a $23...

1M ago

IRD

Opus Genetics announces $23M registered direct offering

The financing, which included new and existing institutional investors, was led by Perceptive Advisors and Balyasny Asset Management,...

1M ago

IRD

IRD FAQ

What was Opus Genetics’s price range in the past 12 months?

Opus Genetics lowest stock price was $0.65 and its highest was $2.59 in the past 12 months.

What is Opus Genetics’s market cap?

Opus Genetics’s market cap is $153.79M.

When is Opus Genetics’s upcoming earnings report date?

Opus Genetics’s upcoming earnings report date is May 08, 2026 which is in 145 days.

How were Opus Genetics’s earnings last quarter?

Opus Genetics released its earnings results on Nov 12, 2025. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.13 by -$0.12.

Is Opus Genetics overvalued?

According to Wall Street analysts Opus Genetics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Opus Genetics pay dividends?

Opus Genetics does not currently pay dividends.

What is Opus Genetics’s EPS estimate?

Opus Genetics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Opus Genetics have?

Opus Genetics has 68,964,210 shares outstanding.

What happened to Opus Genetics’s price movement after its last earnings report?

Opus Genetics reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.13. Following the earnings report the stock price went down -2.538%.

Which hedge fund is a major shareholder of Opus Genetics?

Currently, no hedge funds are holding shares in IRD

Opus Genetics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-338.75%

Trailing 12-Months

Asset Growth

-13.76%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Opus Genetics

Opus Genetics (IRD) is a biotechnology company focused on developing gene therapies for inherited retinal diseases. The company operates within the biopharmaceutical sector, concentrating on creating innovative treatments aimed at restoring vision for patients affected by genetic eye disorders. Its core products are gene therapy solutions that target specific genetic mutations responsible for retinal diseases.

Opus Genetics (IRD) Earnings & Revenues

Historic Earnings Reports

IRD Stock 12 Month Forecast

Average Price Target

$8.00

▲(238.98% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","-1":"-$1","1.75":"$1.75","4.5":"$4.5","7.25":"$7.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.75,4.5,7.25,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2,2.5384615384615383,3.0769230769230766,3.6153846153846154,4.153846153846153,4.692307692307692,5.230769230769231,5.769230769230769,6.3076923076923075,6.846153846153846,7.384615384615384,7.9230769230769225,8.461538461538462,{"y":9,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2,2.4615384615384617,2.9230769230769234,3.3846153846153846,3.8461538461538463,4.307692307692308,4.769230769230769,5.230769230769231,5.6923076923076925,6.153846153846154,6.615384615384616,7.0769230769230775,7.538461538461538,{"y":8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2,2.3076923076923075,2.6153846153846154,2.9230769230769234,3.230769230769231,3.5384615384615383,3.8461538461538463,4.153846153846154,4.461538461538462,4.769230769230769,5.076923076923077,5.384615384615385,5.6923076923076925,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.26,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.15,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.11,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.94,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.09,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.94,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.23,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >